Evaluation of Human Hepatocyte Drug Metabolism Carrying High-Risk or Protection-Associated Liver Disease Genetic Variants
Metabolic-dysfunction-associated steatotic liver disease (MASLD), which affects 30 million people in the US and is anticipated to reach over 100 million by 2030, places a significant financial strain on the healthcare system. There is presently no FDA-approved treatment for MASLD despite its public...
Main Authors: | Lanuza A. P. Faccioli, Zeliha Cetin, Zehra N. Kocas-Kilicarslan, Kimberly Ortiz, Yiyue Sun, Zhiping Hu, Takeshi Kurihara, Edgar N. Tafaleng, Rodrigo M. Florentino, Zi Wang, Mengying Xia, Mark T. Miedel, D. Lansing Taylor, Jaideep Behari, Alina Ostrowska, Robert Constantine, Albert Li, Alejandro Soto-Gutierrez |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-08-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/24/17/13406 |
Similar Items
-
Polymorphisms Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease Influence the Progression of End-Stage Liver Disease
by: Zehra N. Kocas-Kilicarslan, et al.
Published: (2024-01-01) -
Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors
by: Yoshihisa Takahashi, et al.
Published: (2023-10-01) -
Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver diseaseKey points
by: Guillaume Henin, et al.
Published: (2024-02-01) -
Emerging therapies for MASLD and their impact on plasma lipids
by: Madison Nguyen, et al.
Published: (2024-03-01) -
Regulatory T cell: a double-edged sword from metabolic-dysfunction-associated steatohepatitis to hepatocellular carcinoma
by: Han Wang, et al.
Published: (2024-03-01)